Leerink Partnrs Has Pessimistic Outlook of SRPT Q2 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings estimates for Sarepta Therapeutics in a research report issued to clients and investors on Wednesday, July 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will earn $0.72 per share for the quarter, down from their previous forecast of $2.25. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics' Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($2.50) EPS, Q3 2026 earnings at $3.10 EPS, Q4 2026 earnings at $1.56 EPS and FY2026 earnings at $6.63 EPS.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.73 EPS.

Several other equities research analysts have also recently commented on SRPT. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating on the stock in a research report on Tuesday, June 17th. Oppenheimer dropped their target price on shares of Sarepta Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a report on Friday. Bank of America reduced their target price on shares of Sarepta Therapeutics from $28.00 to $20.00 and set a "neutral" rating for the company in a report on Friday. Guggenheim dropped their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Needham & Company LLC lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $56.50.

Sarepta Therapeutics Stock Down 36.0%

SRPT opened at $14.07 on Monday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. The company has a market capitalization of $1.38 billion, a PE ratio of -5.23 and a beta of 0.45. The stock's fifty day moving average is $28.42 and its 200-day moving average is $67.58. Sarepta Therapeutics has a one year low of $12.81 and a one year high of $150.48.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the company. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the first quarter worth $30,000. Center for Financial Planning Inc. acquired a new stake in Sarepta Therapeutics in the 1st quarter worth approximately $31,000. Logan Capital Management Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $61,000. Ancora Advisors LLC grew its holdings in Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. Finally, Hurley Capital LLC bought a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $76,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.